Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients

International Journal of Cancer

Volumn 93, Issue 1, 2001, Pages 80-84

  Seute, Alexander ^a   Sinn, Hans Peter ^b   Schlenk, Richard F ^a   Emig, Robert ^c   Wallwiener, Diethelm ^c   Grischke, Eva Maria ^d   Hohaus, Stefan ^e   Döhner, Hartmut ^a   Haas, Rainer ^f   Bentz, Martin ^a,g  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CATHOLIC UNIVERSITY   (Italy)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g Innere Medizin III   (Germany)

Author keywords

Breast cancer; Chromosomes; Prognosis; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DNA; EPIRUBICIN; ESTROGEN RECEPTOR; IFOSFAMIDE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; FEMALE; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 8; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0035399798     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1296     Document Type: Article

References (39)

1. Routinely available indicators of prognosis in breast cancer
2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies with cytogenetic subtype
3. Human breast cancer: Correlation of relapse and survival with amplification of Her2/neu oncogene
4. Prognostic importance of c-erb-B2 expression in breast cancer
5. Erb-B2, p53, and efficacy of adjuvant therapy in lymph nodepositive breast cancer
6. ErbB2 and response to doxorubicin in patients with axillary lymph nodepositive, hormone receptor-negative breast cancer
7. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
8. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
9. Stage III and estrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer patients
10. Comparative genomic hybridization in chronic B-cell leukemias reveals a high incidence of chromosomal gains and losses
11. Censoring distributions as a measure of follow-up in survival analysis
12. Non-parametric estimation form incomplete observation
13. Asymptotically efficient rank invariant test procedures
14. Regression models and life tables
15. C-myc amplification is an independent prognostic factor in postmenopausal breast cancer
16. P53 mutations occur in aggressive breast cancer
17. Amplification of chromosomal region 20q13 in invasive breast cancer: Prognostic implications
18. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer
19. Molecular cytogenetics of primary breast cancer by CGH
20. Comparative genomic hybridization of ductal carcinoma in situ of the breast - Evidence of multiple genetic pathways
21. Genetic alterations in lobular breast cancer by comparative genomic hybridization
22. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer
23. Genetic aberrations in hypodiploid breast cancer; frequent loss of chromosome 4 and amplification of Cyclin D1 Oncogene
24. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas
25. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization
26. DNA copy number amplifications in human neoplasms
27. DNA copy number losses in human neoplasms
28. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines
29. Comparative genomic hybridization analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data
30. Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer
31. Mapping loss of heterozygosity at chromosome 13q: Loss at 13q12-q13 is associated with breast tumor progression and poor prognosis
32. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer
33. Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes
34. Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer
35. Two-color FISH characterization of i(1q) and der(1;16) in human breast cancer cells
36. der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis
37. Losses on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases
38. Relationship between loss of estrogen and progesterone receptor expression and of 6q and 11q chromosome arms in breast cancer
39. Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions